A universal angular momentum profile for galactic halos

[Abridged] We study the angular-momentum profiles of a statistical sample of halos drawn from a high-resolution N-body simulation of the LCDM cosmology. We find that the cumulative mass distribution of specific angular momentum, j, in a halo of mass Mv is well fit by a universal function, M(<j) = Mv \mu j/(j_0+j). This profile is defined by one shape parameter (\mu or j_0) in addition to the global spin parameter \lambda. It follows a power-law over most of the mass, and flattens at large j, with the flattening more pronounced for small values of \mu. Compared to a uniform sphere in solid-body rotation, most halos have a higher fraction of their mass in the low- and high-j tails of the distribution. The spatial distribution of angular momentum in halos tends to be cylindrical and is well-aligned within each halo for ~80% of the halos. We investigate two ideas for the origin of this profile. The first is based on a revised version of linear tidal-torque theory combined with extended Press-Schechter mass accretion, and the second focuses on j transport in minor mergers. Finally, we briefly explore implications of the M(<j) profile on the formation of galactic disks assuming that j is conserved during an adiabatic baryonic infall. The implied gas density profile deviates from an exponential disk, with a higher density at small radii and a tail extending to large radii. The steep central density profiles may imply disk scale lengths that are smaller than observed. This is reminiscent of the "angular-momentum problem" seen in hydrodynamic simulations, even though we have assumed perfect j conservation. A possible solution is to associate the central excesses with bulge components and the outer regions with extended gaseous disks.Comment: 19 pages LaTeX, uses emulateapj5, 22 embedded figures, 1 separate figure, Submitted to ApJ, version with higher quality figures available at http://www.astronomy.ohio-state.edu/~james/PAPER/parts.htm

Spread of a highly mucoid Streptococcus pyogenes emm3/ST15 clone

<p>Abstract</p> <p>Background</p> <p>Hyaluronic acid capsule plays a key role in <it>Streptococcus pyogenes </it>virulence. Circulation of mucoid or highly encapsulated strains has been related to rheumatic fever epidemics and invasive disease in several countries. In 2009, an outbreak of mucoid <it>S. pyogenes </it>isolates was detected in northern Spain. The aim of the study was to describe clinical and molecular characteristics of mucoid strains causing this outbreak and to compare them with a sample of non-mucoid <it>S. pyogenes </it>isolates obtained during the same period of time.</p> <p>Methods</p> <p>All <it>S. pyogenes </it>isolates with a mucoid colony morphology (n = 132), 10% of non-mucoid (n = 144) and all invasive <it>S. pyogenes </it>isolates (n = 7) obtained in 2009 were included. Characterization was performed by T-agglutination, <it>emm </it>typing, pulsed field gel electrophoresis and multilocus sequence typing.</p> <p>Results</p> <p>One clone characterized as <it>emm</it>3.1/ST15 comprised 98.5% (n = 130) of all mucoid isolates. Subjects of all ages were affected. Main clinical manifestations were pharyngitis and scarlet fever, but this clone also caused invasive disease: two cases of streptococcal toxic shock syndrome, one arthritis, and one celullitis with a fatal outcome. Mucoid isolates were more prone to cause invasive disease than non-mucoid isolates (p = 0.001).</p> <p>Conclusions</p> <p>Although no acute rheumatic fever cases were detected, the most worrisome characteristics of this clone were the success for causing invasive disease and the merge of two virulent features: the serotype, <it>emm</it>3, and capsule hyper-production, expressed as a mucoid morphology.</p

Comparison of NITAG policies and working processes in selected developed countries

BACKGROUND: Vaccines are specific medicines characterized by two country-specific market access processes: (1) a recommendation by National Immunization Technical Advisory Group (NITAG), and (2) a funding policy decision. OBJECTIVES: The objective of this study was to compare and analyze NITAGs of 13 developed countries by describing vaccination committees' bodies and working processes. METHODS: Information about NITAGs bodies and working processes was searched from official sources from June 2011 to November 2012. Retrieved information was completed from relevant articles identified through a systematic literature review and by information provided by direct contact with NITAGs or parent organizations. An expert panel was also conducted to discuss, validate, and provide additional input on obtained results. RESULTS: While complete information, defined as 100%, was retrieved only for the UK, at least 80% of data was retrieved for 9 countries out of the 13 selected countries. Terms of references were identified in 7 countries, and the main mission for all NITAGs was to provide advice for National immunization programs. However, these terms of references did not fully encompass all the actual missions of the NITAGs. Decision analysis frameworks were identified for 10 out of the 13, and all NITAGs considered at least four criteria for decision-making: disease burden, efficacy/effectiveness, safety and cost-effectiveness. Advices were published by most NITAGs, but few NITAGs published meeting agendas and minutes. Only the United States had open meetings. CONCLUSIONS: This study supports previous findings about the disparities in NITAGs processes which could potentially explain the disparity in access to vaccinations and immunization programs across Europe. With NITAGs recommendations being used by policy decision makers for implementation and funding of vaccine programs, guidances should be well-informed and transparent to ensure National Immunization Programs' (NIP) credibility among the public and health care professionals